SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UNH is trending as investors monitor the broader healthcare sector, particularly in anticipation of upcoming earnings reports from sector peers like ELV which may signal the direction of UNH. Community discussions revolve around potential impacts from government shutdowns, ACA subsidies, and the possibility of increased institutional investment following recent filings. Some traders are also expressing concern over regulatory probes and mixed opinions on the stock's short-term and long-term outlook.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

$GSIT is trending following news of its Compute-In-Memory APU achieving GPU-class AI performance with significantly lower energy consumption, sparking excitement about its potential to disrupt the AI semiconductor industry. Community members are discussing the possibility of a multi-day run and a potential partnership or acquisition by a larger player like $NVDA. Some traders are also eyeing the $17.50 resistance level, considering strategies around potential breakouts or reversals.

Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics Inc. is trending as investors anticipate the unveiling of their new AI-powered robot at the upcoming NVIDIA GTC conference, fueling speculation about potential partnerships and advancements in automation. Community discussions revolve around the stock's high short interest and potential for a violent run, with some noting Blackrock's increased share as a positive signal. Others are weighing the company's future prospects against its current market capitalization and revenue.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

General Motors is trending following its Q3 earnings report, which included an EPS and revenue beat, as well as increased guidance. Community members are focused on the company's free cash flow and full-year EBIT outlook. Broader discussion centers on how GM is managing EV production and navigating the impact of tariffs.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices surge, driven by a potential supply squeeze and increasing demand. The community is debating whether this rally is sustainable, with some pointing to manipulation and historical patterns, while others cite strong physical demand and potential for much higher prices. Discussions also include the impact of a weaker dollar and potential safe-haven buying amid broader market concerns.

GIGA is a meme token deployed on the Solana blockchain intended to honor the legend Ernest Khalimov the original “Gigachad”, by utilizing the strength of memes and “Chad” energy.  GIGA is a community run project.

GigaChad

GigaChad is trending as community members express strong bullish sentiment, highlighting its potential for significant gains and drawing comparisons to other successful meme coins like SPX. The community emphasizes GigaChad's strong cultural presence and active engagement, with some pointing to its association with Giga Fitness as a unique value proposition. The recent price action has sparked discussions about potential breakout points and future price targets, with many expressing conviction in its long-term potential.

AlphaVest Acquisition Corp. is a blank check company, which engages in effecting a merger, stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination. The company was founded on January 14, 2022 and is headquartered in New York, NY.

AlphaVest Acquisition Corp

AlphaVest Acquisition Corp ($ATMV) is trending with significant volatility and trading halts, fueled by discussions around a potential merger; some speculate it could run much higher due to its low float. The community is closely watching for breakouts and potential short squeezes, while also cautioning about potential risks associated with SPACs and high volatility.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending due to positive analyst coverage and community excitement around potential breakthroughs in cancer immunotherapy, particularly for prostate cancer. Community members are discussing the company's financial positioning, potential partnerships, and the upcoming data releases for CAN-3110. Some investors believe CADL is significantly undervalued, with potential for substantial returns based on its clinical pipeline and market opportunities.

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Elevance Health Inc

Elevance Health is trending following its Q3 earnings release, which significantly surpassed Wall Street's profit estimates. The community is discussing the implications of the EPS beat, the company's managed medical costs, and the potential for a broader healthcare sector rally. Some are focused on share buybacks and the stock's valuation relative to peers like UNH.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

Shares of NEUP are volatile, experiencing a significant price drop following the announcement that its Phase 3 trial for social anxiety disorder failed to meet endpoints. Despite the negative news, some investors believe the overreaction presents a buying opportunity, citing the company's cash runway through Q2 2027, partnership with Merck for an Alzheimer's drug, and potential in other pipeline products.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CUMBERLAND PHARMACEUTICALS' VIBATIV ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

CUMBERLAND PHARMACEUTICALS' VIBATIV ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC. CUMBERLAND PHARMACEUTICALS' VIBATIV ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC...

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn., Feb. 25, 2025 NASHVILLE, Tenn...

VIBATIV RECEIVES MARKETING APPROVAL IN CHINA

VIBATIV RECEIVES MARKETING APPROVAL IN CHINA VIBATIV RECEIVES MARKETING APPROVAL IN CHINA PR Newswire NASHVILLE, Tenn. and SHANGHAI, Feb. 18, 2025 Vibativ is a life-saving antibiotic for pneumonia...

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease Cumberland Pharmaceuticals Announces Breakthrough Results from...

Shares of Cumberland Pharmaceuticals (CPIX) doubled on Tuesday morning, reaching levels not seen since March 2023, following FDA approval of a new dosing regimen for its liver drug, Acetadote.Acetadote, an intravenous formulation of N-acetylcysteine, helps prevent or mitigate liver injury caused by toxic acetaminophen ingestion.&nbsp;The newly approved regimen combines the first two standard doses into a single, slower infusion, simplifying administration and improving patient outcomes, according to experts.Rick Dart, MD, PhD, Director at the Rocky Mountain Poison and Drug Center, said: "By streamlining the administration of NAC, we can improve patient outcomes and reduce the risk of adverse events. This simplified dosing regimen is a valuable tool for health care providers in managing this potentially life-threatening condition."<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CPIX_sentiment_and_message_volume_Dec_10_64a13aec8e.png" alt="CPIX sentiment and message volume Dec 10.png" width="1318" height="324"><figcaption>CPIX sentiment and message volume Dec 10 as of 10:15 am ET | Source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for Cumberland shot up into ‘extremely bullish’ territory amid a surge in message volume.One user called the latest development “too much big news” to keep the stock between $5-$10 for long.<stembedurl>https://stocktwits.com/cjstocksup/message/595845075</stembedurl>Cumberland has attracted significant retail attention on Stocktwits, with watchlist growth of over 7% and message activity surging by 9,000% in the past year.In addition to Acetadote developments, Cumberland is advancing several Phase II clinical programs evaluating ifetroban, a drug candidate targeting conditions like cardiomyopathy associated with Duchenne Muscular Dystrophy, systemic sclerosis, and idiopathic pulmonary fibrosis.<a href="https://stocktwits.com/symbol/CPIX">Cumberland shares</a> are up nearly 26% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Cumberland Pharma Stock Hits 16-Month High After FDA Approves Liver Drug Regimen: Retail’s Thrilled

The newly approved regimen combines the first two standard doses into a single, slower infusion, simplifying administration and improving patient outcomes, according to experts.

Equity

FDA APPROVES ACETADOTE sNDA

FDA APPROVES ACETADOTE sNDA FDA APPROVES ACETADOTE sNDA PR Newswire NASHVILLE, Tenn., Dec. 9, 2024 - New Dosing Regimen Simplifies Administration - NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire...

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update PR Newswire...

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND...

New Study Compares Caldolor (ibuprofen injection) to ketorolac

New Study Compares Caldolor (ibuprofen injection) to ketorolac New Study Compares Caldolor (ibuprofen injection) to ketorolac PR Newswire NASHVILLE, Tenn., Nov. 5, 2024 Real World Study Compared Over...

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn., Oct. 31, 2024...

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

Cumberland Pharmaceuticals Inc.

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

CPIX
Cumberland Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CPIX News

CPIXCumberland Pharmaceuticals Inc.